Epileptic Disord. 2022 Jun 1;24(3):531-540. doi: 10.1684/epd.2022.1414.
We aimed to determine a possible association between motor and mental development in infants of women with epilepsy and antenatal exposure to antiseizure medication (ASM).
Developmental paediatricians who were blinded to antenatal ASM exposure evaluated motor and mental development of infants (>12 months) using the Developmental Assessment Scale for Indian Infants (an Indian adaptation of the Bayley Scale of Infant Development). Motor (MODQ) and mental development quotients (MEDQ) were computed as ratios of respective developmental age to the chronological age of the child. We employed linear mixed models to study the relationship between antenatal exposure to ASM and the development quotients after adjustment for malformation status and age of the baby, maternal education and seizure type.
We studied 1,357 infants with mean age of 15.3±4.0 months (71.2% of all eligible infants). Infants were classified as having monotherapy or polytherapy, or unexposed in 840, 407 and 110 participants, respectively. The MEDQ of the polytherapy (92.9±14.9) and monotherapy (96.9±13.9) groups was lower than that of unexposed infants (99.8 12.5). Similarly, the MODQ of polytherapy (91.1±19.3) and monotherapy (96.6±17.5) groups was lower than that of unexposed infants (97.6 16.6). The differences in adjusted mean MEDQ were -7.4 (-11.4 to -4.3, p=0.001), -9.6 (-11.3 to -6.0, p=0.001) and -6.4 (-9.2 to -3.7, p=0.001) for valproate monotherapy, polytherapy with valproate and polytherapy without valproate, respectively. The adjusted mean MODQ also showed a similar trend. Those exposed to levetiracetam (n=62) had higher or similar adjusted MODQ (110.4±14.3; p=0.001) and MEDQ (104.3±9.1; p=0.09), compared to unexposed infants. A dose-dependent decrease in developmental indicators was observed for valproate and phenobarbitone.
Antenatal exposure to ASM, especially valproate and phenobarbitone, adversely affects motor and mental development of exposed infants. Early developmental screening of high-risk infants is desirable.
我们旨在确定患有癫痫的女性在产前接触抗癫痫药物(ASM)与婴儿的运动和精神发育之间可能存在的关联。
对运动发育进行盲法评估的发育儿科医生使用印度婴儿发育评估量表(Bayley 婴儿发育量表的印度改编版)评估了(> 12 个月)婴儿的运动和精神发育。运动(MODQ)和精神发育商(MEDQ)分别为发育年龄与儿童实际年龄的比值。我们采用线性混合模型,在校正畸形状态和婴儿年龄、母亲教育和癫痫发作类型后,研究产前暴露于 ASM 与发育商之间的关系。
我们研究了 1357 名平均年龄为 15.3±4.0 个月(所有符合条件婴儿的 71.2%)的婴儿。婴儿分为单药治疗、多药治疗或未暴露于 840、407 和 110 名参与者,分别。多药治疗(92.9±14.9)和单药治疗(96.9±13.9)组的 MEDQ 低于未暴露于婴儿(99.8±12.5)。同样,多药治疗(91.1±19.3)和单药治疗(96.6±17.5)组的 MODQ 也低于未暴露于婴儿(97.6±16.6)。调整后的平均 MEDQ 差异分别为 -7.4(-11.4 至-4.3,p=0.001)、-9.6(-11.3 至-6.0,p=0.001)和-6.4(-9.2 至-3.7,p=0.001),分别为丙戊酸单药治疗、丙戊酸联合多药治疗和无丙戊酸多药治疗。调整后的平均 MODQ 也显示出类似的趋势。与未暴露于婴儿相比,接触左乙拉西坦(n=62)的婴儿具有更高或相似的调整后 MODQ(110.4±14.3;p=0.001)和 MEDQ(104.3±9.1;p=0.09)。观察到丙戊酸和苯巴比妥的剂量依赖性发育指标下降。
产前接触 ASM,尤其是丙戊酸和苯巴比妥,会对暴露于婴儿的运动和精神发育产生不利影响。对高危婴儿进行早期发育筛查是可取的。